Wealthfront Advisers
ALNY icon

Wealthfront Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wealthfront Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.44M Buy
9,898
+344
+4% +$87.5K ﹤0.01% 585
2026
Q2 		$2.88M Sell
9,554
-2,033
-18% -$613K 0.01% 553
2026
Q1 		$3.83M Sell
11,587
-6,667
-37% -$2.27M 0.01% 475
2025
Q4 		$7.26M Buy
18,254
+4,834
+36% +$2.14M 0.02% 311
2025
Q3 		$6.12M Buy
13,420
+1,336
+11% +$544K 0.01% 346
2025
Q2 		$3.94M Buy
12,084
+3,363
+39% +$931K 0.01% 425
2025
Q1 		$2.35M Sell
8,721
-3,899
-31% -$1M 0.01% 500
2024
Q4 		$2.97M Buy
12,620
+4,324
+52% +$1.14M 0.01% 434
2024
Q3 		$2.28M Buy
8,296
+200
+2% +$52.1K 0.01% 473
2024
Q2 		$1.97M Buy
8,096
+6
+0.1% +$947 0.01% 484
2024
Q1 		$1.21M Sell
8,090
-3,495
-30% -$583K ﹤0.01% 578
2023
Q4 		$2.22M Sell
11,585
-772
-6% -$131K 0.01% 440
2023
Q3 		$2.19M Sell
12,357
-15,289
-55% -$2.92M 0.01% 405
2023
Q2 		$5.25M Sell
27,646
-6,667
-19% -$1.32M 0.02% 205
2023
Q1 		$6.87M Buy
34,313
+1,727
+5% +$363K 0.03% 161
2022
Q4 		$7.74M Buy
32,586
+14,210
+77% +$3.03M 0.04% 141
2022
Q3 		$3.68M Buy
18,376
+4,258
+30% +$812K 0.02% 237
2022
Q2 		$2.06M Buy
14,118
+1,273
+10% +$181K 0.01% 375
2022
Q1 		$2.1M Buy
12,845
+11,526
+874% +$1.76M 0.01% 391
2021
Q4 		$224K Buy
+1,319
New +$245K ﹤0.01% 731

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Wealthfront Advisers's ALNY Position: Q3 2026 in Review

Wealthfront Advisers increased its Alnylam Pharmaceuticals (ALNY) stake by 3.6% in Q3 2026, buying an estimated $87.5K and bringing the position to 9,898 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #585.

Wealthfront Advisers first reported a position in ALNY in Q4 2021 and has held it in 20 quarters since. The position peaked at $7.74M in Q4 2022. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Wealthfront Advisers held 9,898 shares of Alnylam Pharmaceuticals worth $2.44M as of Q3 2026.
  • Wealthfront Advisers bought 344 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $87.5K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Wealthfront Advisers's portfolio in Q3 2026, its #585 holding.
  • Wealthfront Advisers first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 20 quarters since.
  • Wealthfront Advisers's Alnylam Pharmaceuticals position peaked at $7.74M in Q4 2022.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Wealthfront Advisers's 13F filing for Q3 2026, filed 9 Nov 2026.